Sydney, Feb 23, 2026, 17:07 AEDT — After-hours.
CSL Ltd (CSL.AX) shares slid 3.8% on Monday to A$147.38. The stock hit A$147.18 at one point, a 52-week low, from a previous close of A$153.27. (Investing)
CSL is one of the Australian market’s biggest healthcare names, and its moves often set the tone for the sector. Monday’s drop came with little company news beyond filings, leaving the stock to trade like a risk barometer into the next session.
The broader S&P/ASX 200 closed down 0.61%, with losses in healthcare, IT and real estate dragging more than gains elsewhere. (Investing.com UK)
Overseas, markets stayed jittery after the U.S. Supreme Court struck down President Donald Trump’s emergency tariffs, and the shifting response from Washington left traders guessing about what rates apply, and when. “The tariff landscape is now more uncertain than before, uncertainty is not good news for any economy or market,” said Rodrigo Catril, a senior FX strategist at National Australia Bank. (Reuters)
CSL said in an ASX filing it bought back 58,583 shares on Feb. 20 for about A$9.0 million, paying between A$150.85 and A$154.07 each. That takes the on-market repurchase to about 3.45 million shares with roughly A$654 million spent so far; CSL said the program is for up to US$750 million and runs until June 30, with UBS acting as broker. (CSL Limited)
Separate director-interest notices showed non-executive directors Constantine Saroukos and Cameron Price received rights under CSL’s director plan. The notices put the volume-weighted average price — a measure that weights trades by size — at A$152.492553. (CSL Limited)
CSL’s slide follows a sharp selloff earlier this month when it reported an 81% drop in first-half profit after one-off charges and weaker blood plasma product and vaccine sales, and CEO Paul McKenzie stepped down. “I’m not prepared to accept that we can’t do better,” interim chief Gordon Naylor told analysts, as the company stuck to its full-year outlook. (Reuters)
But the stock stays exposed if its plasma business does not deliver the second-half lift baked into guidance, or if policy and pricing settings in key markets shift again. A buyback can steady a bid; it can’t do the heavy lifting on earnings.
With the market shut, traders will watch Tuesday for follow-through selling — or a bounce — and for any fresh tariff headlines that could jolt risk appetite again.
CSL shares trade ex-dividend on March 10 — meaning buyers from that day miss the interim payment — with a record date of March 11 and cash due April 9. The next major checkpoint is full-year results and the final dividend call on Aug. 18. (CSL Limited)
